Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-26-003909
Filing Date
2026-05-14
Accepted
2026-05-14 16:01:00
Documents
62
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR MAR 2026 actuate_i10q-033126.htm   iXBRL 10-Q 507007
2 CERTIFICATION actuate_ex3101.htm EX-31.1 7485
3 CERTIFICATION actuate_ex3102.htm EX-31.2 7510
4 CERTIFICATION actuate_ex3201.htm EX-32.1 5550
  Complete submission text file 0001683168-26-003909.txt   3482547

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE actu-20260331.xsd EX-101.SCH 33911
6 XBRL CALCULATION FILE actu-20260331_cal.xml EX-101.CAL 36783
7 XBRL DEFINITION FILE actu-20260331_def.xml EX-101.DEF 117150
8 XBRL LABEL FILE actu-20260331_lab.xml EX-101.LAB 268866
9 XBRL PRESENTATION FILE actu-20260331_pre.xml EX-101.PRE 240152
66 EXTRACTED XBRL INSTANCE DOCUMENT actuate_i10q-033126_htm.xml XML 353181
Mailing Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107
Business Address 1751 RIVER RUN SUITE 400 FORT WORTH TX 76107 847-986-4190
ACTUATE THERAPEUTICS, INC. (Filer) CIK: 0001652935 (see all company filings)

EIN.: 473044785 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42139 | Film No.: 26978523
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)